Drugs / MYDAYIS
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MYDAYIS | — | 2017-06-20 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03945175 | Jul 2020 → May 2022 | attention deficit-hyperactivity disorder | NYU Langone Health | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04235686 Comparator | Jul 2020 → Jul 2025 | bipolar depression | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mydayis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04235686 ↗ |
| Route | Oral | “MYDAYIS®, Oral administration” NCT04235686 ↗ |